ENTRADA THERAPEUTICS, INC.

ENTRADA THERAPEUTICS, INC.

Entrada Therapeutics develops treatments for metabolic diseases.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts suggest buying Entrada Therapeutics' stock as it has great potential for growth.

Above Average

Financial Health

Entrada Therapeutics is generating solid revenue and cash flow, indicating good financial performance.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring TRDA

Orphan Drug Moats: Leaders In Rare Disease

Orphan Drug Moats: Leaders In Rare Disease

The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.

Published: August 20, 2025

Explore Basket
Gene Therapy's Competitive Shift

Gene Therapy's Competitive Shift

The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.

Published: July 25, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Platform Potential

A delivery platform could expand which diseases are treatable and create licensing opportunities, though technical and clinical validation remain crucial.

Early-stage Programme

Progress in preclinical or early clinical programmes can be catalytic for valuation, but outcomes are uncertain and timelines can be lengthy.

🌍

Partnering & Licensing

Collaborations can de‑risk development and provide funding; however, deal terms, milestones and future financing needs are important considerations.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

VRTX

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.

REGN

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.

ALNY

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).

Frequently asked questions